The Taxotere lawsuit is a mass of product liability claims accusing Sanofi-Aventis of hiding that its chemotherapy drug docetaxel, sold under the brand name Taxotere, can cause permanent hair loss and serious tear duct injuries. Thousands of patients have sued, and the cases are consolidated into two federal multidistrict litigations in the Eastern District of Louisiana. As of mid-2026, no global settlement has been announced in either.
What Plaintiffs Say Sanofi Did Wrong
The core claim is a failure to warn. Before December 2015, Taxotere’s U.S. label told patients that “hair generally grows back” after treatment. Plaintiffs say Sanofi knew that was not true for a meaningful share of patients and stayed quiet anyway.
The evidence they point to is the timing. A company-funded clinical trial known as GEICAM 9805, with results available as early as 2005, found that 9.2% of patients treated with high-dose docetaxel had hair loss lasting ten years or longer. Sanofi updated its permanent hair loss warnings in Canada in 2005 and in Europe in 2012. The U.S. label was not updated until December 11, 2015, when the FDA approved a supplemental change adding the language “cases of permanent alopecia have been reported” to the postmarketing experience section and patient counseling materials.
Plaintiffs allege Sanofi “knowingly, intentionally, and wrongfully withheld” the GEICAM results from American patients and doctors during the decade in between.
The Two Injuries at the Center of the Litigation
Permanent Hair Loss
The condition at issue is permanent chemotherapy-induced alopecia, defined as absent or incomplete hair regrowth six months or more after treatment ends. It is not ordinary chemo shedding, which reverses.
Published research supports the link. A UK retrospective survey of 383 breast cancer patients found 23.3% of those who received docetaxel reported permanent hair loss, compared with 10.1% of those who received paclitaxel. Taxane-based treatments as a class are associated with roughly eight times the likelihood of causing permanent alopecia compared with other chemotherapy drugs. The risk rises with dose: among patients who received a cumulative dose above 400 mg/m², between 35% and 52% experienced some degree of persistent hair thinning, and about 10% had complete alopecia severe enough to require a wig.
Tear Duct Damage
A separate group of lawsuits alleges Taxotere damages the lacrimal system, the drainage pathway for tears. The specific injuries are punctal, canalicular, and nasolacrimal duct stenosis, in which the tear ducts narrow or scar shut. Patients experience chronic excessive tearing and eye irritation, and in advanced cases the condition does not resolve after stopping the drug. Treatment can range from stenting procedures to full surgical reconstruction of the drainage pathway.
The science here is not new. Researchers first described canalicular stenosis as a side effect of docetaxel therapy in 2001. A 2002 study in the Annals of Oncology confirmed that docetaxel is secreted in the tear film, where direct contact causes chronic inflammation and fibrosis. Up to 50% of patients receiving weekly docetaxel therapy have reported excessive tearing symptoms.
Where the Cases Stand
The Hair Loss MDL
In October 2016, the Judicial Panel on Multidistrict Litigation consolidated hair loss lawsuits into MDL 2740 in the Eastern District of Louisiana. The proceeding now sits before Judge Jane Triche Milazzo. At its peak the MDL held more than 15,500 individual actions. As of June 2026, 282 cases remain pending out of 15,572 total filings, a 98% resolution rate, with the court remanding remaining cases back to their original districts in waves.
Two bellwether trials have gone to a jury, and Sanofi won both. In Barbara Earnest v. Sanofi, a September 2019 jury found the plaintiff had not proven Taxotere caused her permanent hair loss. In a second bellwether involving plaintiff Elizabeth Kahn, a November 2021 jury found Sanofi had provided adequate warnings.
The Earnest verdict did not stand. In February 2022, the Fifth Circuit reversed and ordered a new trial, finding Sanofi had made “a calculated and troubling end-run around Rule 702 and Daubert” by presenting corporate representative Dr. Michael Kopreski as a lay witness to deliver what was effectively expert scientific testimony. Kopreski had performed a litigation-driven reanalysis of the TAX316 clinical trial that narrowed the number of patients with ongoing hair loss from 29 to six. The Earnest case then settled at a June 2022 conference and was dismissed without prejudice. Kahn appealed her defense verdict in December 2021, and that appeal was still pending before the Fifth Circuit as of late 2022.
Sanofi’s biggest legal argument going forward is preemption: that federal drug labeling law barred it from adding a permanent hair loss warning without prior FDA approval. Judge Milazzo denied summary judgment on that ground in August 2022, and the Fifth Circuit was set to review the preemption question as of March 2026.
No global settlement has been announced. Individual cases have settled, including Earnest on remand, but terms are not public.
The Eye Injury MDL
In early 2022, the Judicial Panel on Multidistrict Litigation refused to fold the eye injury cases into the hair loss MDL. Instead it created a separate proceeding, MDL 3023, also before Judge Milazzo. About 150 eye injury cases were pending as of June 2026.
These cases have room to run. In December 2025, Judge Milazzo denied Sanofi’s motion for summary judgment, letting the claims move toward possible trials. In April 2026, the court granted summary judgment to four generic docetaxel manufacturers, narrowing the defendants but keeping Sanofi in.
State Courts
New Jersey designated Taxotere cases as multicounty litigation in July 2018, centralizing them in Middlesex County. New Jersey courts have been strict on timing, dismissing claims as time-barred under a two-year statute of limitations and treating the clock as starting six months after chemotherapy ends, once permanent alopecia is considered established. Arguments to toll the statute until the 2015 label change or until a plaintiff consulted a lawyer have been rejected. Cases have also proceeded in Delaware, with 53 remanded from the federal MDL as of mid-2020.
Who May Still Be Able to File
Eligibility generally requires that you received docetaxel for cancer treatment and afterward developed either permanent or long-term hair loss, or a serious eye injury such as tear duct stenosis. The strongest claims have involved patients treated before the December 2015 U.S. label update, on the theory that anyone treated afterward received a warning about the permanent alopecia risk.
Timing is the biggest obstacle. Statute of limitations rules vary by state and have been a frequent basis for dismissal, as the New Jersey rulings show. If you had docetaxel years ago and noticed persistent hair loss or tear problems long before consulting a lawyer, a court may find the clock already ran. Anyone considering a claim should get a lawyer to evaluate the state deadline that would apply to their case before assuming a filing is still open.
A note on scope: generic docetaxel manufacturers face a different set of legal questions than Sanofi does about their ability to change label warnings independently, and in the eye injury MDL four generics have already been dismissed on summary judgment. Which manufacturer supplied the drug can matter to whether a case survives.